Full video transcriptClick to expand
Auto-generated transcript of @sophisticatedmama's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Week 2 results.
- 0:10Seven pounds, week one.
- 0:13Four pounds, week two.
- 0:1411 pounds, so.
- 0:16What is the plan?
- 0:18What am I following?
- 0:19What am I doing?
- 0:19Nothing.
- 0:21Nothing.
- 0:23I eat when I'm hungry and I don't when I'm not.
- 0:25I try to eat protein every time I do try to eat something,
- 0:29and that's it.
- 0:31This medication is designed to suppress your appetite.
- 0:34And if it works for you, it suppresses your appetite.
- 0:37So I'm becoming one of those people that just doesn't need all the time.
- 0:43It's somebody I don't recognize, but I like it so far.
Saxenda and appetite suppression: what TikTok gets wrong
Quick answer
Saxenda (liraglutide 3.0 mg) is an FDA-approved GLP-1 receptor agonist for chronic weight management that works primarily by reducing appetite through central and peripheral mechanisms. The creator's reported 11-pound loss over two weeks is consistent with early treatment response, though this figure almost certainly includes substantial water weight rather than adipose tissue alone. Her self-directed protein prioritization approach is clinically reasonable but insufficient as a substitute for structured nutritional guidance during GLP-1 therapy.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda and appetite suppression: what TikTok gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda and appetite suppression: what TikTok gets wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Saxenda and appetite suppression: what TikTok gets wrong" from Mara 🇨🇦. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Saxenda (liraglutide 3.
The reason this review is not generic is the source wording and the canonical claim label "glp1 who am i if i m not eating weightlossmedication saxenda weig." In this clip, the useful excerpt is: "Week 2 results." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Saxenda (liraglutide 3.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Saxenda (liraglutide 3.0 mg) is an FDA-approved GLP-1 receptor agonist for chronic weight management that works primarily by reducing appetite through central and peripheral mechanisms. The creator's reported 11-pound loss over two weeks is consistent with early treatment response, though this figure almost certainly includes substantial water weight rather than adipose tissue alone. Her self-directed protein prioritization approach is clinically reasonable but insufficient as a substitute for structured nutritional guidance during GLP-1 therapy.
- Early weight loss on liraglutide frequently exceeds 5-7 lbs in week one due to water weight and glycogen loss, not fat loss alone. Long-term average fat loss is closer to 5-8% of body weight over 56 weeks (Pi-Sunyer et al., 2015, NEJM).
- Liraglutide (Saxenda) and semaglutide (Wegovy) are both GLP-1 receptor agonists but are not clinically equivalent. Saxenda is a daily injection; Wegovy is weekly. Their efficacy data comes from separate trial programs and should not be compared using social media results.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Early weight loss on liraglutide frequently exceeds 5-7 lbs in week one due to water weight and glycogen loss, not fat loss alone. Long-term average fat loss is closer to 5-8% of body weight over 56 weeks (Pi-Sunyer et al., 2015, NEJM).
- Liraglutide (Saxenda) and semaglutide (Wegovy) are both GLP-1 receptor agonists but are not clinically equivalent. Saxenda is a daily injection; Wegovy is weekly. Their efficacy data comes from separate trial programs and should not be compared using social media results.
- Appetite suppression on GLP-1 medications can reduce total caloric intake below levels needed to sustain adequate protein and micronutrient intake. Patients relying solely on hunger cues may undereat essential nutrients without realizing it.
- Protein intake during GLP-1 therapy is not just a preference, it is a clinical priority. Research indicates that patients on appetite-suppressing medications face elevated risk of lean muscle loss without deliberate protein targeting (Moon et al., 2023, Nutrients).
- Saxenda requires titration from 0.6 mg to 3.0 mg over approximately five weeks. Appetite suppression and side effects both change significantly across the titration period, meaning week 2 results may not reflect the full treatment experience.
- Approximately 15-20% of liraglutide users in clinical trials are non-responders who lose less than 5% of body weight. The creator's caveat, 'if it works for you,' is more accurate than most GLP-1 content online.
- Compounded versions of liraglutide are not FDA-approved and have not been tested for bioequivalence with Saxenda. Clinical outcomes described in trials and in this video apply to the brand-name formulation only.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @sophisticatedmama actually say?
She reported losing 7 pounds in week one and 4 pounds in week two, totaling 11 pounds, while following "nothing" in terms of a structured diet. Her core claim is simple: Saxenda suppressed her appetite so effectively that she now eats only when hungry, prioritizes protein when she does eat, and has become "one of those people that just doesn't eat all the time." She frames this as a personality transformation, not a diet plan.
To her credit, she is not selling a protocol. She is describing her lived experience accurately and without overclaiming. She does not say this will work for everyone, and she does not recommend doses or specific eating windows. That restraint matters on a platform where GLP-1 content frequently drifts into dangerous territory.
Does the science back this up?
Mostly yes, with some important caveats about those early numbers. Liraglutide, the active ingredient in Saxenda, does measurably reduce appetite and caloric intake by acting on GLP-1 receptors in the hypothalamus and gut. That part is not disputed.
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed that patients on 3.0 mg liraglutide lost an average of 8.4 kg over 56 weeks compared to 2.8 kg on placebo. That is meaningful weight loss, but it is spread over more than a year. Losing 11 pounds in two weeks, while not impossible, almost certainly reflects a significant amount of water weight and glycogen depletion, not 11 pounds of fat tissue. To lose that much actual fat, you would need a caloric deficit of roughly 38,500 calories in 14 days, which is physiologically implausible without starvation-level restriction.
Her appetite suppression experience, though, tracks directly with the mechanism. Liraglutide slows gastric emptying and reduces hunger signals. Forni et al. (2023, Obesity Reviews) confirmed that GLP-1 receptor agonists significantly reduce ad libitum caloric intake in clinical populations.
What did they get wrong (or right)?
She got the appetite suppression mechanism right. "This medication is designed to suppress your appetite" is accurate for liraglutide. That is not a coincidental benefit; it is the primary driver of weight loss in GLP-1 receptor agonists.
What she got wrong, or at least incomplete, is the framing around the 11-pound figure. Presenting that number without distinguishing between water weight and fat loss is misleading to viewers who may expect similar results. Early rapid loss on GLP-1 medications is well documented but is not predictive of sustained fat loss. The SCALE trial data suggests the average patient loses closer to 5-8% of body weight over the full treatment course, not 11 pounds in a fortnight.
Her protein-first approach, though casual, is actually supported. Adequate protein intake during GLP-1 therapy helps preserve lean muscle mass when caloric intake drops sharply. Moon et al. (2023, Nutrients) noted that protein adequacy is a significant concern for patients on appetite-suppressing medications who may undereat across all macronutrients without realizing it.
What should you actually know?
Three things matter here for anyone watching this video and considering Saxenda.
- Early weight loss on GLP-1 medications is partly water weight. The scale will move fast at first. That does not mean you will lose 11 pounds every two weeks. Expect a significant slowdown after the first month.
- "Eating when hungry" sounds effortless, but suppressed appetite can mask inadequate nutrition. Patients on liraglutide who do not track protein and micronutrient intake risk muscle loss and nutritional deficiencies over time, particularly if they are not working with a provider.
- Saxenda requires dose titration over several weeks to reach the therapeutic 3.0 mg dose. Results vary significantly depending on where in that titration a patient is. The video does not mention dose, which is relevant context for understanding why her appetite response may intensify or change over coming weeks.
Saxenda is also not Wegovy or Ozempic. Liraglutide is a daily injection with a shorter half-life than semaglutide. The clinical outcomes differ, and the two drugs should not be treated as interchangeable based on social media results.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Mara 🇨🇦 · TikTok creator
50.2K views on this video
Who am I if I'm not eating? #weightlossmedication #saxenda #weightlossjourney
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about early weight loss on liraglutide frequently exceeds 5-7 lbs in?
Early weight loss on liraglutide frequently exceeds 5-7 lbs in week one due to water weight and glycogen loss, not fat loss alone. Long-term average fat loss is closer to 5-8% of body weight over 56 weeks (Pi-Sunyer et al., 2015, NEJM).
What does the video say about liraglutide (saxenda)?
Liraglutide (Saxenda) and semaglutide (Wegovy) are both GLP-1 receptor agonists but are not clinically equivalent. Saxenda is a daily injection; Wegovy is weekly. Their efficacy data comes from separate trial programs and should not be compared using social media results.
What does the video say about appetite suppression on glp-1 medications can reduce total caloric intake?
Appetite suppression on GLP-1 medications can reduce total caloric intake below levels needed to sustain adequate protein and micronutrient intake. Patients relying solely on hunger cues may undereat essential nutrients without realizing it.
What does the video say about protein intake during glp-1 therapy?
Protein intake during GLP-1 therapy is not just a preference, it is a clinical priority. Research indicates that patients on appetite-suppressing medications face elevated risk of lean muscle loss without deliberate protein targeting (Moon et al., 2023, Nutrients).
What does the video say about saxenda requires titration from 0.6 mg to 3.0 mg over?
Saxenda requires titration from 0.6 mg to 3.0 mg over approximately five weeks. Appetite suppression and side effects both change significantly across the titration period, meaning week 2 results may not reflect the full treatment experience.
What does the video say about approximately 15-20% of liraglutide users in clinical trials?
Approximately 15-20% of liraglutide users in clinical trials are non-responders who lose less than 5% of body weight. The creator's caveat, 'if it works for you,' is more accurate than most GLP-1 content online.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Mara 🇨🇦, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.